BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024
Earnings Report: Boundless Bio (NASDAQ:BOLD) reported a second-quarter 2024 earnings per share of -77 cents, surpassing analyst expectations of -80 cents, but did not generate any revenue for the quarter.
Automated Coverage: InvestorPlace Earnings utilizes TradeSmith data to automate the reporting of quarterly earnings, providing quick insights on key financial figures without human intervention.
Trade with 70% Backtested Accuracy
Analyst Views on BOLD
About BOLD
About the author
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
POTENTIATE Trial Enrollment: Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of the POTENTIATE trial, expecting to deliver initial proof-of-concept clinical data within its cash runway timeline.
Financial Overview: The company reported a net loss of $15.7 million for Q2 2025, with $127 million in cash supporting operations through expected clinical readouts into 2028.
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Appointment of Carolyn Ng: Carolyn Ng has been appointed to the external advisory board of the Rice Biotech Launch Pad, bringing her extensive experience in biotech and company building to support the accelerator's mission of translating health and medical technology discoveries into effective therapies.
Role of the Rice Biotech Launch Pad: The Rice Biotech Launch Pad aims to expedite the transition of innovative research from Rice University into clinical studies and commercialization, contributing to Houston's growth as a leading biotech hub.
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Company Announcement: Boundless Bio, a clinical-stage oncology company, will have its CEO Zachary Hornby participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, in Miami, FL.
Research Focus: The company is dedicated to developing therapies targeting extrachromosomal DNA (ecDNA) in oncogene amplified cancers, with ongoing clinical trials for their therapeutic candidates BBI-355 and BBI-825.
Leerink Partners Downgrades Boundless Bio to Market Perform, Lowers Price Target to $3
Real-time Trading Intelligence: Benzinga Pro offers the fastest and most accurate stock market news alerts to help traders succeed in their investments.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.
Boundless Bio Announces Portfolio Prioritization and Runway Extension
Portfolio Updates: Boundless Bio is prioritizing the combination therapy of BBI-355 and BBI-825 while discontinuing current arms of the POTENTIATE clinical trial. The company has also declared BBI-940 as a development candidate for its novel Kinesin program, with plans to submit an IND application in early 2026.
Operational Changes: The company's operational streamlining, including a workforce reduction, aims to extend its cash runway into the first half of 2028, allowing time to achieve proof-of-concept clinical milestones for its therapeutic programs.
Guggenheim Sticks to Its Hold Rating for Boundless Bio Inc. (BOLD)
Analyst Rating: Guggenheim analyst Michael Schmidt has maintained a Hold rating on Boundless Bio Inc., with the company's shares closing at $1.50, while the consensus remains a Hold.
Company Performance: Boundless Bio has experienced significant fluctuations in its stock price over the past year, reaching a high of $14.72 and a low of $1.42, with an average trading volume of 73.36K.
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
POTENTIATE Trial Enrollment: Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of the POTENTIATE trial, expecting to deliver initial proof-of-concept clinical data within its cash runway timeline.
Financial Overview: The company reported a net loss of $15.7 million for Q2 2025, with $127 million in cash supporting operations through expected clinical readouts into 2028.
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Appointment of Carolyn Ng: Carolyn Ng has been appointed to the external advisory board of the Rice Biotech Launch Pad, bringing her extensive experience in biotech and company building to support the accelerator's mission of translating health and medical technology discoveries into effective therapies.
Role of the Rice Biotech Launch Pad: The Rice Biotech Launch Pad aims to expedite the transition of innovative research from Rice University into clinical studies and commercialization, contributing to Houston's growth as a leading biotech hub.
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Company Announcement: Boundless Bio, a clinical-stage oncology company, will have its CEO Zachary Hornby participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, in Miami, FL.
Research Focus: The company is dedicated to developing therapies targeting extrachromosomal DNA (ecDNA) in oncogene amplified cancers, with ongoing clinical trials for their therapeutic candidates BBI-355 and BBI-825.
Leerink Partners Downgrades Boundless Bio to Market Perform, Lowers Price Target to $3
Real-time Trading Intelligence: Benzinga Pro offers the fastest and most accurate stock market news alerts to help traders succeed in their investments.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.
Boundless Bio Announces Portfolio Prioritization and Runway Extension
Portfolio Updates: Boundless Bio is prioritizing the combination therapy of BBI-355 and BBI-825 while discontinuing current arms of the POTENTIATE clinical trial. The company has also declared BBI-940 as a development candidate for its novel Kinesin program, with plans to submit an IND application in early 2026.
Operational Changes: The company's operational streamlining, including a workforce reduction, aims to extend its cash runway into the first half of 2028, allowing time to achieve proof-of-concept clinical milestones for its therapeutic programs.
Guggenheim Sticks to Its Hold Rating for Boundless Bio Inc. (BOLD)
Analyst Rating: Guggenheim analyst Michael Schmidt has maintained a Hold rating on Boundless Bio Inc., with the company's shares closing at $1.50, while the consensus remains a Hold.
Company Performance: Boundless Bio has experienced significant fluctuations in its stock price over the past year, reaching a high of $14.72 and a low of $1.42, with an average trading volume of 73.36K.
